tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

PharmaCyte Biotech CEO & CSO Interview – Discussion of IND, Cell Encapsulation, Clinical Trial Design, CRO, and More

PharmaCyte Biotech CEO & CSO Interview – Discussion of IND, Cell Encapsulation, Clinical Trial Design, CRO, and More

Written by Ι Stock Market Media — May 30, 2018

Today Stock Market Media Group is releasing its latest Interview in our series of CEO Interviews.  Today we welcome PharmaCyte Biotech (OTCQB: PMCB) a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, and the company’s Chief Executive Officer, Kenneth L. Waggoner, and its Chief Scientific Officer, Prof. Walter H. Günzburg.

Click Here to Listen ...

Read More →
0

PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

Written by Ι Stock Market Media — May 21, 2018

PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application (IND) to the U.S. FDA.  It’s an IND that has been eagerly anticipated by the company’s shareholders since PharmaCyte met with the FDA in early 2017, and it would lay out PharmaCyte’s planned Phase 2b clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC.

The key ...

Read More →
0

SPYR, Inc. Finding Its Niche in Mobile Gaming Using Popular Branded IP inside Popular Genres

SPYR, Inc. Finding Its Niche in Mobile Gaming Using Popular Branded IP inside Popular Genres

Written by Ι Stock Market Media — April 3, 2018

NEW YORK, NY – SPYR, Inc. (OTCQB: SPYR) has decided that one aspect of its business model in the mobile games space will be to bring popular intellectual property or “IP” associated with Hollywood and television to the games it’s publishing. It’s difficult for any digital games company to gain traction in what is a hyper-competitive industry; however, SPYR is implementing a proven strategy to get its games recognized by many consumers ...

Read More →
0

SPYR’s Focus on Mobile Games Has Company Ideally Positioned to Grow within Game Industry’s Global Market

SPYR’s Focus on Mobile Games Has Company Ideally Positioned to Grow within Game Industry’s Global Market

Written by Ι Stock Market Media — July 13, 2017

SPYR, Inc. (OTCQB: SPYR) has already made a big splash in the mobile games space when it published its flagship real time, true cross platform, MMO game Pocket Starships. And since then, the company has continued to broaden the game’s appeal with its Hivespawn update, a worldwide marketing and advertising campaign, and now SPYR is set to make the game even more popular with a number of future updates.

These updates will allow Pocket ...

Read More →
0

CBS Consumer Products Shows Confidence in SPYR’s Pocket Starships with Licensing Deal for Star Trek IP

CBS Consumer Products Shows Confidence in SPYR’s Pocket Starships with Licensing Deal for Star Trek IP

Written by Ι Stock Market Media — June 14, 2017

SPYR, Inc. (OTCQB: SPYR) received what should be viewed as a vote of confidence from CBS Consumer Products in a recently announced licensing deal between the two companies. CBS is licensing its intellectual property (IP) from the long-running Star Trek television series: Star Trek: The Next Generation, Star Trek: Deep Space Nine and Star Trek: Voyager to SPYR, which can be taken as a vote of confidence by CBS Consumer Products in ...

Read More →
0

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Written by Ι Stock Market Media — May 18, 2017

Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare® Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Plandaí should expect to receive its own positive data. The two studies could complement one another, and Plandaí’s ...

Read More →
0
Page 2 of 31 12345...»
ContactUs.com ContactUs.com